Jenburkt Pharmaceuticals Intrinsic Value
Jenburkt Pharmaceuticals intrinsic value. Jenburkt Pharmaceuticals (JENBURPH) median intrinsic value is ₹985.00 from 10 valuation models (range ₹499–₹1637), vs current price ₹900.40 — +9.4% upside (Trading Near Calculated Value), margin of safety 8.6%. Read JENBURPH ex-dividend dates for the complete payout history and dividend yield track record.
JENBURPH Valuation Methods Summary — DCF, Graham Number & P/E
Jenburkt Pharmaceuticals intrinsic value across 10 models vs current price ₹900.40 — upside/downside and value range per method. For current market price and key ratios, visit Jenburkt Pharmaceuticals share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1636.80 | ₹1309.44 - ₹1964.16 | +81.8% | EPS: ₹74.40, Sector P/E: 22x |
| Book Value Method | asset | ₹985.00 | ₹886.50 - ₹1083.50 | +9.4% | Book Value/Share: ₹492.50, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹890.00 | ₹801.00 - ₹979.00 | -1.2% | Revenue/Share: ₹445.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1175.00 | ₹1057.50 - ₹1292.50 | +30.5% | EBITDA: ₹47.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹916.88 | ₹733.50 - ₹1100.26 | +1.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹499.47 | ₹449.52 - ₹549.42 | -44.5% | EPS Growth: 8.4%, Fair P/E: 6.7x |
| Growth Adjusted P/E | growth | ₹1148.43 | ₹1033.59 - ₹1263.27 | +27.5% | Revenue Growth: 5.8%, Adj P/E: 15.4x |
| ROE Based Valuation | profitability | ₹1155.00 | ₹1039.50 - ₹1270.50 | +28.3% | ROE: 16.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹907.99 | ₹817.19 - ₹998.79 | +0.8% | EPS: ₹74.40, BVPS: ₹492.50 |
| Dividend Yield Method | dividend | ₹828.00 | ₹745.20 - ₹910.80 | -8.0% | DPS: ₹20.70, Target Yield: 2.5% |
JENBURPH Intrinsic Value vs Market Price — All Valuation Models
Jenburkt Pharmaceuticals fair value range ₹499–₹1637 vs current market price ₹900.40 across 10 valuation models. Compare with Jenburkt Pharmaceuticals valuation methods to assess whether the stock is under or overvalued.
JENBURPH Intrinsic Value Analysis — Undervalued or Overvalued?
Jenburkt Pharmaceuticals median intrinsic value ₹985.00, current price ₹900.40 — Trading Near Calculated Value by 9.4%, margin of safety 8.6%.
What is the intrinsic value of JENBURPH?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Jenburkt Pharmaceuticals (JENBURPH) is ₹985.00 (median value). With the current market price of ₹900.40, this represents a +9.4% variance from our estimated fair value.
The valuation range spans from ₹499.47 to ₹1636.80, indicating ₹499.47 - ₹1636.80.
Is JENBURPH undervalued or overvalued?
Based on our multi-method analysis, Jenburkt Pharmaceuticals (JENBURPH) appears to be trading near calculated value by approximately 9.4%.
JENBURPH Financial Health — Key Ratios vs Industry Benchmarks
Jenburkt Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 15.83 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 16.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 22.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.79x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
JENBURPH Cash Flow Quality — Operating & Free Cash Flow
Jenburkt Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹27 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹28 Cr | ₹20 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹17 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹9 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |